Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia

Autor:	Raphael Preiss, Johannes Thaler, Petra Jilma, Ingrid Pabinger, Eva Mikušková, Peter Quehenberger, Stephan Kudrnovsky-Moser, Florian Roitner, Joachim Rettl, Nazanin Samadi, Paul Knoebl, Cihan Ay
Rok vydání:	2021
Předmět:	medicine.medical_specialty biology Long term follow up business.industry Hematology medicine.disease Gastroenterology Thrombosis Immune thrombocytopenia Vaccination Internal medicine medicine biology.protein In patient Antibody business Venous thromboembolism Platelet factor 4
Zdroj:	Thrombosis Research. 207:126-130
ISSN:	0049-3848
Popis:	BACKGROUND: Cases of ChAdOx1 nCoV-19 (AstraZeneca) vaccinated patients with thrombocytopenia, elevated D-dimer, and elevated platelet factor 4 (PF4) antibody levels with- and without thrombosis have been reported. No recommendations regarding the duration of anticoagulation have been made, because data on the long-term course beyond the first weeks is lacking. OBJECTIVE: To report on the treatment, medical course, and longitudinal follow-up of laboratory parameters in patients with vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). PATIENTS: We followed VIPIT patients with- (n = 3) and without (n = 3) venous thromboembolism fulfilling the aforementioned laboratory criteria. RESULTS: Elevated D-dimer (median: 35.10 µg/ml, range: 17.80-52.70), thrombocytopenia (42 G/l, 20-101), and strong positivity in the platelet factor 4 (PF4)/heparin-enzyme-immunoassay (2.42 optical density [OD], 2.06-3.13; reference range
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::796a8b9f5d794b11fe912efb5bc21408 https://doi.org/10.1016/j.thromres.2021.09.017 Zobrazit plný text záznamu Full Text from ScienceDirect